{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=anti-PD-1+therapy&page=6", "query": { "intervention": "anti-PD-1 therapy", "page": 6 }, "page_size": 10 }, "pagination": { "page": 6, "page_size": 10, "total_count": 527, "total_pages": 53, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=anti-PD-1+therapy&page=7&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=anti-PD-1+therapy&page=5&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-13T04:37:40.129Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03817125", "title": "Melanoma Checkpoint and Gut Microbiome Alteration With Microbiome Intervention", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Metastatic Melanoma" ], "interventions": [ { "name": "Placebo for antibiotic", "type": "DRUG" }, { "name": "Vancomycin pretreatment", "type": "DRUG" }, { "name": "Nivolumab", "type": "DRUG" }, { "name": "Matching Placebo for SER-401", "type": "DRUG" }, { "name": "SER-401", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Parker Institute for Cancer Immunotherapy", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 14, "start_date": "2019-01-28", "completion_date": "2022-03-04", "has_results": true, "last_update_posted_date": "2024-06-06", "last_synced_at": "2026-10-13T04:37:40.129Z", "location_count": 7, "location_summary": "Los Angeles, California • Boston, Massachusetts • New Brunswick, New Jersey + 3 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "New Brunswick", "state": "New Jersey" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT03817125" }, { "nct_id": "NCT04673448", "title": "Niraparib and TSR-042 for the Treatment of BRCA-Mutated Unresectable or Metastatic Breast, Pancreas, Ovary, Fallopian Tube, or Primary Peritoneal Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Anatomic Stage III Breast Cancer AJCC v8", "Anatomic Stage IV Breast Cancer AJCC v8", "BRCA-Associated Malignant Neoplasm", "BRCA Hereditary Ovarian Carcinoma", "Metastatic BRCA Hereditary Breast Carcinoma", "Metastatic Breast Carcinoma", "Metastatic Fallopian Tube Carcinoma", "Metastatic Malignant Solid Neoplasm", "Metastatic Ovarian Carcinoma", "Metastatic Pancreatic Carcinoma", "Metastatic Primary Peritoneal Carcinoma", "Prognostic Stage III Breast Cancer AJCC v8", "Prognostic Stage IV Breast Cancer AJCC v8", "Stage III Fallopian Tube Cancer AJCC v8", "Stage III Ovarian Cancer AJCC v8", "Stage III Pancreatic Cancer AJCC v8", "Stage III Primary Peritoneal Cancer AJCC v8", "Stage IV Fallopian Tube Cancer AJCC v8", "Stage IV Ovarian Cancer AJCC v8", "Stage IV Pancreatic Cancer AJCC v8", "Stage IV Primary Peritoneal Cancer AJCC v8", "Unresectable Breast Carcinoma", "Unresectable Fallopian Tube Carcinoma", "Unresectable Malignant Solid Neoplasm", "Unresectable Ovarian Carcinoma", "Unresectable Pancreatic Carcinoma", "Unresectable Primary Peritoneal Carcinoma" ], "interventions": [ { "name": "Dostarlimab", "type": "BIOLOGICAL" }, { "name": "Niraparib", "type": "DRUG" }, { "name": "Biopsy", "type": "PROCEDURE" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "PROCEDURE" ], "sponsor": "University of Washington", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 18, "start_date": "2021-10-18", "completion_date": "2027-09-30", "has_results": false, "last_update_posted_date": "2026-08-20", "last_synced_at": "2026-10-13T04:37:40.129Z", "location_count": 1, "location_summary": "Seattle, Washington", "locations": [ { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT04673448" }, { "nct_id": "NCT05785767", "title": "A Study to Learn if a Combination of Fianlimab and Cemiplimab Versus Cemiplimab Alone is More Effective for Adult Participants With Advanced Non-Small Cell Lung Cancer (NSCLC)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Advanced Non-Small Cell Lung Cancer" ], "interventions": [ { "name": "fianlimab", "type": "DRUG" }, { "name": "cemiplimab", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Regeneron Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 149, "start_date": "2023-06-30", "completion_date": "2027-09-28", "has_results": false, "last_update_posted_date": "2026-07-02", "last_synced_at": "2026-10-13T04:37:40.129Z", "location_count": 23, "location_summary": "Tucson, Arizona • Yuma, Arizona • Redlands, California + 20 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Yuma", "state": "Arizona" }, { "city": "Redlands", "state": "California" }, { "city": "Norwich", "state": "Connecticut" }, { "city": "Clermont", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT05785767" }, { "nct_id": "NCT04242199", "title": "Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099280 in Participants With Advanced Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Solid Tumor", "MSI-H/dMMR Tumors", "Cutaneous Squamous Cell Carcinoma", "Urothelial Carcinoma", "Cervical Cancer", "HepatoCellular Carcinoma", "Esophageal Squamous Cell Carcinoma", "Merkel Cell Carcinoma", "Small-cell Lung Cancer", "Mesothelioma", "PD-L1 Amplified Tumor (9p24.1)", "Nasopharyngeal Carcinoma" ], "interventions": [ { "name": "INCB099280", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Incyte Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 182, "start_date": "2020-09-04", "completion_date": "2024-11-21", "has_results": false, "last_update_posted_date": "2025-07-14", "last_synced_at": "2026-10-13T04:37:40.129Z", "location_count": 5, "location_summary": "Boston, Massachusetts • Detroit, Michigan • Pittsburgh, Pennsylvania + 2 more", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Detroit", "state": "Michigan" }, { "city": "Pittsburgh", "state": "Pennsylvania" }, { "city": "Houston", "state": "Texas" }, { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT04242199" }, { "nct_id": "NCT05060432", "title": "Study of EOS-448 With Standard of Care and/or Investigational Therapies in Participants With Advanced Solid Tumors", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Advanced Cancer", "Lung Cancer", "Head and Neck Cancer", "Melanoma" ], "interventions": [ { "name": "EOS-448", "type": "DRUG" }, { "name": "pembrolizumab", "type": "DRUG" }, { "name": "inupadenant", "type": "DRUG" }, { "name": "Dostarlimab", "type": "DRUG" }, { "name": "SOC chemotherapies", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "iTeos Belgium SA", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 153, "start_date": "2021-09-06", "completion_date": "2025-07", "has_results": false, "last_update_posted_date": "2024-06-21", "last_synced_at": "2026-10-13T04:37:40.129Z", "location_count": 2, "location_summary": "San Diego, California • Bergen, New Jersey", "locations": [ { "city": "San Diego", "state": "California" }, { "city": "Bergen", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT05060432" }, { "nct_id": "NCT02423863", "title": "In Situ, Autologous Therapeutic Vaccination Against Solid Cancers With Intratumoral Hiltonol®", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Melanoma", "Head and Neck Cancer", "Sarcoma", "Non-Melanoma Skin Cancers" ], "interventions": [ { "name": "Hiltonol", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Oncovir, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 26, "start_date": "2015-03", "completion_date": "2020-08-31", "has_results": false, "last_update_posted_date": "2020-12-17", "last_synced_at": "2026-10-13T04:37:40.129Z", "location_count": 5, "location_summary": "Chevy Chase, Maryland • Easton, Maryland • Columbia, Missouri + 1 more", "locations": [ { "city": "Chevy Chase", "state": "Maryland" }, { "city": "Chevy Chase", "state": "Maryland" }, { "city": "Easton", "state": "Maryland" }, { "city": "Columbia", "state": "Missouri" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT02423863" }, { "nct_id": "NCT07288034", "title": "Immunotherapy Biomarkers to Predict First-line PD(L)1-based Immunotherapy Response and Selection of Second-line Treatment in Stage IIIB-IV Non-small Cell Lung Cancer, IMMUNO-BIOMAP Trial", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Lung Non-Small Cell Carcinoma", "Stage IIIB Lung Cancer AJCC v8", "Stage IV Lung Cancer AJCC v8" ], "interventions": [ { "name": "Adagrasib", "type": "DRUG" }, { "name": "Anti-PD-L1 Monoclonal Antibody", "type": "BIOLOGICAL" }, { "name": "Anti-PD1 Monoclonal Antibody", "type": "BIOLOGICAL" }, { "name": "Bevacizumab", "type": "BIOLOGICAL" }, { "name": "Biopsy Procedure", "type": "PROCEDURE" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Chemotherapy", "type": "DRUG" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Durvalumab", "type": "BIOLOGICAL" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Monitoring", "type": "OTHER" }, { "name": "Positron Emission Tomography", "type": "PROCEDURE" }, { "name": "Surveillance", "type": "BEHAVIORAL" }, { "name": "Tremelimumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL", "PROCEDURE", "OTHER", "BEHAVIORAL" ], "sponsor": "City of Hope Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 535, "start_date": "2026-04-08", "completion_date": "2028-10-08", "has_results": false, "last_update_posted_date": "2026-04-15", "last_synced_at": "2026-10-13T04:37:40.129Z", "location_count": 13, "location_summary": "Goodyear, Arizona • Corona, California • Duarte, California + 10 more", "locations": [ { "city": "Goodyear", "state": "Arizona" }, { "city": "Corona", "state": "California" }, { "city": "Duarte", "state": "California" }, { "city": "Huntington Beach", "state": "California" }, { "city": "Irvine", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT07288034" }, { "nct_id": "NCT06425926", "title": "Safety and Tolerability Study of GIM-531 in Advanced Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Melanoma Stage IV", "Solid Tumor" ], "interventions": [ { "name": "GIM-531", "type": "DRUG" }, { "name": "Anti-PD-1 monoclonal antibody", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Georgiamune Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 117, "start_date": "2024-05-09", "completion_date": "2027-11", "has_results": false, "last_update_posted_date": "2026-08-14", "last_synced_at": "2026-10-13T04:37:40.129Z", "location_count": 11, "location_summary": "Scottsdale, Arizona • Bakersfield, California • Fullerton, California + 8 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Bakersfield", "state": "California" }, { "city": "Fullerton", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06425926" }, { "nct_id": "NCT02842125", "title": "Safety and Efficacy of Intra-Arterial and Intra-Tumoral Ad-p53 With Capecitabine (Xeloda) or Anti-PD-1 in Liver Metastases of Solid Tumors and Recurrent Head and Neck Squamous Cell Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Metastatic Solid Tumor Cancer", "Recurrent Head and Neck Cancer" ], "interventions": [ { "name": "Ad-P53", "type": "DRUG" }, { "name": "Xeloda", "type": "DRUG" }, { "name": "Keytruda", "type": "DRUG" }, { "name": "Opdivo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "MultiVir, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 4, "start_date": "2018-11-20", "completion_date": "2020-05-08", "has_results": false, "last_update_posted_date": "2020-06-02", "last_synced_at": "2026-10-13T04:37:40.129Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02842125" }, { "nct_id": "NCT03334617", "title": "Phase II Umbrella Study of Novel Anti-cancer Agents in Participants With NSCLC Who Progressed on an Anti-PD-1/PD-L1 Containing Therapy", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Non-Small Cell Lung Cancer" ], "interventions": [ { "name": "Durvalumab", "type": "DRUG" }, { "name": "Danvatirsen", "type": "DRUG" }, { "name": "Ceralasertib", "type": "DRUG" }, { "name": "Vistusertib", "type": "DRUG" }, { "name": "Olaparib", "type": "DRUG" }, { "name": "Oleclumab", "type": "DRUG" }, { "name": "Trastuzumab deruxtecan", "type": "DRUG" }, { "name": "Cediranib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "99 Years", "sex": "ALL", "summary": "18 Years to 99 Years" }, "enrollment_count": 528, "start_date": "2017-12-18", "completion_date": "2026-09-11", "has_results": true, "last_update_posted_date": "2025-10-27", "last_synced_at": "2026-10-13T04:37:40.129Z", "location_count": 17, "location_summary": "Duarte, California • Fullerton, California • La Jolla, California + 12 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Fullerton", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" } ], "official_url": "https://clinicaltrials.gov/study/NCT03334617" } ] }